Cytokinetics Inc (NASDAQ: CYTK) kicked off on Friday, up 6.55% from the previous trading day, before settling in for the closing price of $49.75. Over the past 52 weeks, CYTK has traded in a range of $29.31-$59.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.02% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -6.67%. With a float of $117.02 million, this company’s outstanding shares have now reached $119.60 million.
Cytokinetics Inc (CYTK) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 2.22%, while institutional ownership is 114.24%. The most recent insider transaction that took place on Sep 02 ’25, was worth 337,800. In this transaction Director of this company sold 6,756 shares at a rate of $50.00, taking the stock ownership to the 23,230 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Director proposed sale 4,300 for $35.33, making the entire transaction worth $151,919.
Cytokinetics Inc (CYTK) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.36 earnings per share (EPS), lower than consensus estimate (set at -1.24) by -0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.60% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 6.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 73.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.12, a number that is poised to hit -1.58 in the next quarter and is forecasted to reach -5.72 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 5.66 million. That was better than the volume of 1.86 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 93.81%.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 95.99%, which indicates a significant increase from 94.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.29 in the past 14 days, which was higher than the 1.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.59, while its 200-day Moving Average is $41.15. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $54.72. Second resistance stands at $56.43. The third major resistance level sits at $58.86. If the price goes on to break the first support level at $50.58, it is likely to go to the next support level at $48.15. Assuming the price breaks the second support level, the third support level stands at $46.44.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 6.34 billion has total of 119,657K Shares Outstanding. Its annual sales at the moment are 18,470 K in contrast with the sum of -589,530 K annual income. Company’s last quarter sales were recorded 66,770 K and last quarter income was -134,370 K.
